Patents by Inventor Lingyu Tai

Lingyu Tai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240068075
    Abstract: A corrosion-resistant nickel alloy is provided. The alloy includes the following components in percentage by mass: 4.68-5.35% of B, 5.69-6.41% of W, 27.68-28.39% of Cr, 12.65-13.42% of Al, and the balance of Ni and inevitable impurities. The corrosion-resistant nickel alloy is a Ni—W—B ternary alloy with main components of Ni, W and B, wherein the three elements have strong high-temperature corrosion resistance at a temperature of about 600° C., and have the potential of solid solution hardening and precipitate formation because all belong to solid solution forming elements, so that a creep strength of a nickel alloy matrix is improved. Meanwhile, Al and Cr are further added in the alloy formula, so that Al2O3 and Cr2O3 oxide layers can be formed, which play a role as a physical diffusion barrier against chlorine gas and other corrosive gases.
    Type: Application
    Filed: November 9, 2023
    Publication date: February 29, 2024
    Applicant: Hainan University
    Inventors: Wenchao MA, Terrence Wenga, Sixuan ZENG, Xingcai CHEN, Lingyu TAI
  • Patent number: 11826431
    Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: November 28, 2023
    Assignee: FUDAN UNIVERSITY
    Inventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao
  • Publication number: 20220008546
    Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.
    Type: Application
    Filed: August 24, 2021
    Publication date: January 13, 2022
    Inventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao
  • Patent number: 11213591
    Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 4, 2022
    Assignee: FUDAN UNIVERSITY
    Inventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao
  • Publication number: 20200237925
    Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 30, 2020
    Inventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao